Journal of Translational Medicine · 2007 · 71 citations · 18 references
Life SciencesDermatologyImmunologyAutoimmunityImmunotherapyInflammationAdaptive Immune ResponsesAutoimmune DiseasesCell-mediated ImmunityEffector T Cell FunctionImmunological MemoryT Cell ActivationCentral Memory T CellsEffector Memory T CellsImmune Memory MaintenanceImmunologic MemoryNaive T CellsPsoriasis ImmunopathologyPsoriasis TherapyPsoriatic Disease
BACKGROUND: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. METHODS: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. RESULTS: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA+) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-gamma-producing) were also significantly reduced. CONCLUSION: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
18
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Federica Sallusto, Danielle Lenig, Reinhold Förster et al. · Nature · 1999 · 5.8K citations
Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells
Dörte Hamann, Paul A. Baars, M.H.G. Rep et al. · The Journal of Experimental Medicine · 1997 · 1.4K citations · Full text
Lisa M. Austin, Maki Ozawa, Toyoko Kikuchi et al. · Journal of Investigative Dermatology · 1999 · 483 citations · Full text
Medicine, Dermatology, Immunology +17